Enveda, a company using artificial intelligence to boost nature-based drug discovery, is envisioning clinical success with a $130 million series C fundraising round.
The round was led by Kinnevik and FPV with other new and existing investors such as Dimension Capital, Lux Capital and The Nature Conservancy also taking part, the company said in a Nov. 21 release.
Enveda has 10 drug candidates currently in development, according to the release, and sent its lead candidate ENV-294 into a phase 1 trial for atopic dermatitis and other inflammatory conditions at the end of October.
The Boulder, Colorado-based biotech plans to use the raise to usher more drugs into the clinic in 2025 and 2026, according to the release.
“We developed our platform to rapidly expand access to nature’s chemistry to find therapeutics at roughly four times the speed–and it’s already delivering results in the form of a deep…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Researchers Take Diagnosis of Pediatric Sepsis to the Next Level
Pediatric sepsis, a major inflammatory response to trauma that can cause organ failure and tissue death, kills about 3.3 million children each year worldwide. The catastrophic overreactions to infection or injury often hit lower-resource clinics […]
Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award
ENGLEWOOD, Colo., April 2, 2024 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced […]
Colorado BioScience Association to Recognize Outstanding Companies and Leaders at Annual Awards Celebration
Aktiv Pharma Group, BioIntelliSense, and Umoja Biopharma Selected as Finalists for Company of the Year; Enveda Biosciences, Think Bioscience, and Watchmaker Genomics Honored as Finalists for Rising Star of the Year Award Denver – […]
